Pfizer buying spree continues with $5.4B hematology deal
The Pfizer logo is displayed on the exterior of a former Pfizer factory, on May 4, 2014, in the Brooklyn borough of New York. Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic. Both companies' boards have approved the deal, which still needs regulatory approval and approval from GBT shareholders. (AP Photo/Mark Lennihan, File)
By TOM MURPHY and MICHELLE CHAPMAN
Associated Press
Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic...
Become a Subscriber!
You have read all of your free articles this month. Select a plan below to start your subscription today.
Already a subscriber? Login
